D
David B. Meya
Researcher at College of Health Sciences, Bahrain
Publications - 227
Citations - 6161
David B. Meya is an academic researcher from College of Health Sciences, Bahrain. The author has contributed to research in topics: Meningitis & Medicine. The author has an hindex of 35, co-authored 185 publications receiving 4795 citations. Previous affiliations of David B. Meya include Makerere University & University of Minnesota.
Papers
More filters
Journal ArticleDOI
Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis
David R. Boulware,David B. Meya,David B. Meya,Conrad Muzoora,Melissa A. Rolfes,Katherine Huppler Hullsiek,Abdu K Musubire,Kabanda Taseera,Henry W. Nabeta,Charlotte Schutz,Darlisha A. Williams,Darlisha A. Williams,Radha Rajasingham,Joshua Rhein,Friedrich Thienemann,Melanie W. Lo,Melanie W. Lo,Kirsten Nielsen,Tracy L. Bergemann,Andrew Kambugu,Yukari C. Manabe,Yukari C. Manabe,Edward N. Janoff,Edward N. Janoff,Paul R. Bohjanen,Graeme Meintjes,Graeme Meintjes +26 more
TL;DR: Deferring ART for 5 weeks after the diagnosis of cryptococcal meningitis was associated with significantly improved survival, as compared with initiating ART at 1 to 2 weeks, especially among patients with a paucity of white cells in cerebrospinal fluid.
Journal ArticleDOI
Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral Therapy
Andrew Kambugu,David B. Meya,Joshua Rhein,Meagan O’Brien,Edward N. Janoff,Allan R. Ronald,Allan R. Ronald,Moses R. Kamya,Harriet Mayanja-Kizza,Merle A. Sande,Paul R. Bohjanen,David R. Boulware +11 more
TL;DR: Significant CM-associated mortality persists, despite the administration of amphotericin B and HIV therapy, because of the high mortality rate before receipt of HAART and because of immune reconstitution inflammatory syndrome-related complications after HAART initiation.
Journal ArticleDOI
Cost-Effectiveness of Serum Cryptococcal Antigen Screening to Prevent Deaths among HIV-Infected Persons with a CD4+ Cell Count ≤100 Cells/μL Who Start HIV Therapy in Resource-Limited Settings
David B. Meya,Yukari C. Manabe,Yukari C. Manabe,Barbara Castelnuovo,Bethany Cook,Ali Elbireer,Ali Elbireer,Andrew Kambugu,Andrew Kambugu,Moses R. Kamya,Paul R. Bohjanen,David R. Boulware +11 more
TL;DR: The number needed to test and treat with CRAG screening and fluconazole to prevent 1 CM case is 11.3 (95% CI, 7.9−17.1) at costs of $190 (95%) CI, $132−$287.
Journal ArticleDOI
Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.
David R. Boulware,David B. Meya,David B. Meya,Tracy L. Bergemann,Darin L. Wiesner,Joshua Rhein,Abdu K Musubire,Sarah J. Lee,Andrew Kambugu,Andrew Kambugu,Edward N. Janoff,Paul R. Bohjanen +11 more
TL;DR: Clinical features in a prospective cohort with AIDS and recent cryptococcal meningitis after initiation of antiretroviral therapy are investigated to identify biomarkers for prediction and diagnosis of CM-IRIS (cryptococcal meninigitis-related immune reconstitution inflammatory syndrome).
Journal ArticleDOI
Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast.
David R. Boulware,Melissa A. Rolfes,Radha Rajasingham,Maximilian von Hohenberg,Zhenpeng Qin,Kabanda Taseera,Charlotte Schutz,Richard Kwizera,Elissa K. Butler,Graeme Meintjes,Conrad Muzoora,John C. Bischof,David B. Meya +12 more
TL;DR: This assay is a major advance in the diagnosis of cryptococcal meningitis and will be used in clinical trials for further studies to establish a causative agent for this disease.